Lupin presents Phase 3 clinical trial data for Solosec; stock dips 2%

The trial results showed a clinically and statistically significant response rate, or microbiological cure, in patients treated with Solosec as compared to placebo (p<0.001).

from India Infoline News Service https://ift.tt/2PX54p8